Pharmaceuticals

Global Protein Degradation Therapy Market 2026 evolving with targeted treatment innovations

March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Protein Degradation Therapy Market By 2030 Starting From Its 2026 Size?

The protein degradation therapy market has seen significant expansion in recent years. It is anticipated to grow from $1.25 billion in 2025 to $1.35 billion in 2026, at a compound annual growth rate (CAGR) of 8.1%. This past growth can be attributed to advancements in molecular biology research, the expansion of targeted cancer therapies, an increased understanding of protein dysfunction in diseases, early-stage clinical successes, and growing venture capital funding in biotech.

The protein degradation therapy market is poised for significant expansion in the coming years, projected to reach $1.83 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This anticipated growth is driven by factors such as a heightened demand for innovative cancer treatments, increasing investments in precision oncology, the broadening scope of protein degradation platforms, an uptick in clinical trial activity, and greater regulatory backing for advanced therapeutics. Key trends during this period are expected to encompass the accelerated development of targeted protein degraders, a sharpened focus on oncology applications, increased capital flowing into PROTAC-based therapies, an expanding pipeline of clinical candidates, and strengthened partnerships between pharmaceutical and biotechnology companies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20603&type=smp

What Drivers Are Shaping The Future Growth Of The Protein Degradation Therapy Market?

The increasing burden of cancer is projected to drive the expansion of the protein degradation therapy market. Cancer refers to a collection of illnesses defined by the uncontrolled multiplication and spread of abnormal cells within the body. The rise in cancer rates is primarily attributable to multiple elements, with the aging population being a major contributor. Additionally, lifestyle habits such as smoking, inadequate diet, lack of exercise, and increasing rates of obesity have heightened the risk of various cancers. Protein degradation therapy is essential for cancer treatment because it selectively targets and eliminates specific proteins that promote cancer growth and survival, potentially overcoming resistance to conventional therapies. For instance, in February 2024, a report from the World Health Organization, a Switzerland-based intergovernmental organization, predicted that over 35 million new cancer cases are expected by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Furthermore, high human development index (HDI) countries are anticipated to experience the largest growth in absolute numbers, with an additional 4.8 million new cases forecast in 2050 compared to 2022 estimates. Therefore, the growing incidence of cancer is propelling the growth of the protein degradation therapy market.

Which Segment Categories Define The Protein Degradation Therapy Market?

The protein degradation therapy market covered in this report is segmented –

1) By Type: Bavdegalutamide (ARV – 110), Vepdegestrant (ARV – 471)

2) By Application: Oncology, Neurodegenerative Diseases, Infectious Diseases, Other Applications

3) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders, Prostate Cancer Therapy

2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders, Breast Cancer Therapy

What Major Market Trends Are Driving Changes In The Protein Degradation Therapy Market?

Leading companies within the protein degradation therapy market are increasingly adopting a strategic alliance approach to foster the creation of novel treatments. These collaborations enable them to utilize complementary expertise, pool resources, and expedite the identification and advancement of new drug candidates aimed at disease-causing proteins. Such strategic partnerships involve organizations leveraging each other’s capabilities and assets for reciprocal advantages and collective achievements. For instance, in February 2024, Arvinas, a U.S.-based biotechnology firm, unveiled its inaugural oral PROTAC degrader, ARV-102. This innovative compound is specifically engineered to penetrate the blood-brain barrier and target LRRK2, intended for applications in neurodegenerative diseases. ARV-102 exhibits oral bioavailability, a brain-penetrant characteristic, and significant specificity for LRRK2. While this advancement enhances companies’ product pipelines by addressing targets previously considered intractable, challenges persist regarding long-term safety, manufacturing intricacies, and the refinement of pharmacokinetics given its larger molecular architecture.

Who Are The Top Companies Competing In The Protein Degradation Therapy Market?

Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc

Read the full protein degradation therapy market report here:

https://www.thebusinessresearchcompany.com/report/protein-degradation-therapy-global-market-report

Which Geographic Regions Are Influencing Demand In The Protein Degradation Therapy Market?

North America was the largest region in the protein degradation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Protein Degradation Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20603&type=smp

Browse Through More Reports Similar to the Global Protein Degradation Therapy Market 2026, By The Business Research Company

Home Infusion Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/home-infusion-therapy-global-market-report

Car T Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/car-t-therapy-global-market-report

Aromatherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/aromatherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795